467223-90-1

Usage

Uses

Used in Research Applications:
1-(3,5-DIFLUOROPHENYL)ETHANOL is used as a research chemical for studying its properties and potential applications in various fields. Its unique structure and reactivity make it an interesting subject for scientific investigation.
Used in Pharmaceutical Applications:
1-(3,5-DIFLUOROPHENYL)ETHANOL is used as an intermediate or building block in the synthesis of pharmaceutical compounds. Its presence in these compounds may contribute to their overall efficacy and properties, such as solubility, stability, and bioavailability.
Used in Chemical Synthesis:
1-(3,5-DIFLUOROPHENYL)ETHANOL is used as a reagent in the synthesis of other organic compounds, particularly those that require the introduction of a fluorophenyl group. Its unique reactivity due to the fluorine atoms may facilitate specific chemical reactions and transformations.

InChI:InChI=1/C4H4Br2F4/c1-3(6,7)2(5)4(8,9)10/h2H,1H3

Upstream product

• 105184-38-1 3,5-difluorophenyl acetic acid 

Downstream Products

• 467223-93-4 3,5-difluorophenethyl iodine 
• 869663-22-9 tri(1-methylethyl)silyl 2-[3,5-difluoro-4-(ethoxyimino-methyl) phenyl]ethyl ether 
• 869663-21-8 2,6-difluoro-4-[2-[tri(1-methylethyl)silyloxy]ethyl]benz-aldehyde 
• 869663-23-0 2-[3,5-difluoro-4-(ethoxyiminomethyl)phenyl]ethanol 
• 1395992-22-9 tert-butyl(3,5-difluorophenethoxy)dimethylsilane 
• 109346-94-3 2-(3,5-difluorophenyl)acetaldehyde 
• 869663-20-7 tri(1-methylethyl)silyl 2-(3,5-difluorophenyl)ethyl ether 
• 467224-08-4 (+)-octahydro-3,6α-dimethyl-3,12-epoxy-9β-(3'-(3,5-difluorophenyl)propyl)-12H-pyrano[4,3j]-1,2-benzodioxepin-10(3H)-one 
• 467224-00-6 C₂₃H₃₀F₂O₅ 

Relevant academic research and scientific papers

Synthetic Ion Channel Formed by Multiblock Amphiphile with Anisotropic Dual-Stimuli-Responsiveness

Transmembrane proteins within biological membranes exhibit varieties of important functions that are vital for many cellular activities, and the development of their synthetic mimetics allows for deep understanding in related biological events. Inspired by the structures and functions of natural ion channels that can respond to multiple stimuli in an anisotropic manner, we developed multiblock amphiphile VF in this study. When VF was incorporated into the lipid bilayer membranes, VF formed a supramolecular ion channel whose ion transport property was controllable by the polarity and amplitude of the applied voltage. Microscopic emission spectroscopy revealed that VF changed its molecular conformation in response to the applied voltage. Furthermore, the ion transport property of VF could be reversibly switched by the addition of (R)-propranolol, an aromatic amine known as an antiarrhythmic agent, followed by the addition of β-cyclodextrin for its removal. The highly regulated orientation of VF allowed for an anisotropic dual-stimuli-responsiveness for the first time as a synthetic ion channel.

Novel pyrrolidine or piperidine derivatives having activity for T-type calcium channel

A pyrrolidine or piperidine compound having activity for T - type calcium channel, wherein the pyrrolidine or piperidine compound of Formula 1 according to the present invention has an excellent antagonistic activity to, T-type calcium channel, and can be used as a preventive or therapeutic agent, for pain diseases, or cancer related to cancer, or cancer such as, epilepsy and,hepatic pain, angina. (by machine translation)

Small Molecule Analogs of the Nemo Binding Peptide

The invention is directed to a method of inhibiting, within a living cell, the interaction between NF-κB essential modulator (“NEMO”) with IκB kinase-β (IKK-β) at the NEMO binding domain (NBD), comprising exposing the cell to an effective amount or concentration of a compound of the invention, a NEMO-binding domain analog (NBDA). The invention is further directed to a method of treating a condition in a patient, wherein inhibiting the interaction between NF-κB essential modulator (“NEMO”) with IκB kinase-β (IKK-β) at the NEMO binding domain (NBD) is medically indicated, comprising administering to the patient an effective dose of a compound of the invention. Conditions that can be treated by a method of the invention includes muscular dystrophy, asthma, inflammatory bowel disease, multiple sclerosis, Parkinson's Disease, arthritis, diabetes, graft versus host disease, accelerated aging, heart ischemia, cancer, UV-induced skin damage, or an age-related pathology.

Synthesis and biological evaluation of pyrrolidine-based T-type calcium channel inhibitors for the treatment of neuropathic pain

The treatment of neuropathic pain is one of the urgent unmet medical needs and T-type calcium channels are promising therapeutic targets for neuropathic pain. Several potent T-type channel inhibitors showed promising in vivo efficacy in neuropathic pain a

SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS

The invention relates to novel compounds and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

INSECTICIDAL DIAZOLE AND TRIAZOLE DERIVATIVES

It has now been found that certain novel diazole and triazole derivatives have provided unexpected insecticidal activity. These compounds are represented by formula (I). Preferred are those compounds of formula (I) where M and Q are carbon; R is methyl; R

ARTEMISININ-BASED PEROXIDE COMPOUNDS AS BROAD SPECTRUM ANTI-INFECTIVE AGENTS

Described herein is the synthesis, bioassay results and utility of new C-9 and C-10 substituted artemisinin derivatives with easily functionalizable groups attached to the artemisinin skeleton through carbon chain or heteroatoms. Described also is the demonstration of this class of compounds for their broad-spectrum anti-parasitic activity. Certain of these analogs possess noticeable cytotoxicity deliberately focused on treatment of cancerous diseases.

Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates

On the basis of earlier reported quantitative structure-activity relationship studies, a series of 9β-16-(arylalkyl)-10-deoxoartemisinins were proposed for synthesis. Several of the new compounds 7 and 10-14 were synthesized employing the key synthetic intermediate 23. In a second approach, the natural product (+)-artemisinic acid was utilized as an acceptor for conjugate addition, and the resultant homologated acids were subjected to singlet oxygenation and acid treatment to provide artemisinin analogues. Under a new approach, we developed a one step reaction for the interconversion of artemisinin 1 into artemisitene 22 that did not employ selenium-based reagents and found that 2-arylethyliodides would undergo facile radical-induced conjugate addition to the exomethylene lactone of 22 in good yield. The lactone carbonyls were removed sequentially by diisobutylaluminum hydride reduction followed directly by a second reduction (BF3-etherate/Et3SiH) to afford the desired corresponding pyrans. Six additional halogen-substituted aromatic side chains were installed via 22 furnishing the bioassay candidates 15-20. The analogues were examined for in vitro antimalarial activity in the W-2 and D-6 clones of Plasmodium falciparum and were additionally tested in vivo in Plasmodium berghei- and/or Plasmodium yoelii-infected mice. Several of the compounds emerged as highly potent orally active candidates without obvious toxicity. Of these, two were chosen for pharmacokinetic evaluation, 14 and 17.